Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc.HEPA · Entity 8208 | Director · VP, Corp. Dev. | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hepion Pharmaceuticals, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2036-08-19 | Direct | 1,345,500 |
Reported balance
After 2026-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 1,345,500 · Balance 1,345,500 F1: 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 20:33 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 1,345,500 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001493152-26-039701 · ownership.xml · derivative · entry 1 LoPriore Chase · CIK 0002136903 · Director · VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,345,500 Underlying: Common Stock · 1,345,500 shares Expires 2036-08-19 F1 · derivative.exercise_date: 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.